In the past year, the cancer program recruited several senior- and junior-level medical scientists.
Among them are these prominent senior-level researchers:
Marcos de Lima, MD, was recruited from Case Western Reserve University to serve as a professor in the Department of Internal Medicine, Division of Hematology at Ohio State and as director of both the Blood and Marrow Transplant (BMT) and Cellular Therapy programs at the OSUCCC – James. Before joining the OSUCCC – James, de Lima was co-leader of the Hematopoietic and Immune Cancer Biology Program at Case Comprehensive Cancer Center, director of the Bone Marrow Transplant Program at University Hospitals Cleveland Medical Center, and director of the Hematologic Malignancies and Stem Cell Transplant Program at University Hospitals Seidman Cancer Center. He has years of experience in developing and conducting clinical trials involving stem cell transplantation for cancers originating in blood-borne tissue, bone marrow or immune system cells.
Mark Rubinstein, PhD, was recruited from the Medical University of South Carolina (MUSC) and the Hollings Cancer Center to serve as an associate professor in the Department of Internal Medicine, Division of Medical Oncology at Ohio State and as a researcher in the Pelotonia Institute for Immuno-Oncology (PIIO) at the OSUCCC – James, where he also is in the Translational Therapeutics Program. Rubinstein’s NIH-funded research program is focused on understanding how the immune system functions and on applying this knowledge to the development of immune-based therapies to treat cancer. As part of this effort, his laboratory is working to develop improved adoptive cell therapy and immune checkpoint therapy strategies.
Joyce Wu, PhD, joined Ohio State as a professor in the Department of Internal Medicine, Division of Rheumatology and Immunology. She was recruited from the University of Arizona Arthritis Center, where she served as an associate professor in the Department of Immunobiology. Trained at Harvard Medical School, and awarded multiple grants from the NIH, Wu focuses her research on microbiome, immune regulation, autoimmunity and cancer.
Ryan Goerlitz, MBA, was chosen as the new chief financial officer (CFO) for the OSUCCC – James in place of Julian Bell, who retired at the end of June after 23 years as CFO. Goerlitz has served as associate vice president of finance for the Ohio State College of Medicine, Office of Health Sciences and Ohio State University Physicians (OSUP) within the Ohio State Wexner Medical Center since he came to the university in 2018 from the Medical College of Wisconsin, where he had worked for 11 years. In his previous role at Ohio State, Goerlitz provided strategic oversight of financial planning, budgeting and financial management for the areas he served.